Compare Citius Pharmaceuticals Inc (CTXR) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Icl Group Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Icl Group Ltd trades at $5.02 (market cap $6.47B). The key difference: Icl Group Ltd is far larger — about 475× Citius Pharmaceuticals Inc's market cap, and Icl Group Ltd pays a 4.11% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Icl Group Ltd for 56 Days on average.
| CTXR | ICL | |
|---|---|---|
Market Cap | $13.62M | $6.47B |
Volume | 132,438 | 1,387,140 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $6.84 |
52-Week Low | $0.48 | $4.80 |
Typical Hold Time | 17 Days | 56 Days |
Enterprise Value | $3.79M | $9.11B |
Dividend Yield | — | 4.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
ICL trades at $5.00, down 1.57% today, with a bearish technical signal from moving averages but a neutral oscillator stance. Recent earnings beat estimates in Q1 and Q2 2026, though revenue and net income have trended lower from 2022 peaks. The company maintains a dividend, with a $0.06 payment scheduled for September 2026, and operates with stable cash flow from operations around $1.1 billion.
The outlook is mixed: valuation ratios like P/E of 20.83 and P/S of 0.84 suggest reasonable pricing, but analyst consensus is entirely Hold with a $6.08 target. Risks include industry headwinds from higher input costs and competitive pressures, while institutional buying, like Amundi's Q1 2026 purchase, offers support. Earnings growth and cost transformation are key to upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
